Men with PRL-producing macroadenomas often present with hypogonadism and impotence. This report documents exacerbation of a PRL-secreting tumor after two separate 200-mg testosterone enanthate (T) injections despite continued bromocriptine (BRC) therapy. A 37-yr-old man with a 60-mm invasive tumor and a serum PRL level of 13,969 +/- 332 ng/ml (mean +/- SD) responded to BRC therapy with rapid disappearance of visual field defect, headache, and facial pain as well as decrease in serum PRL to 5,103 +/- 1,446 ng/ml. T injection was followed by severe headache, facial pain, and increase in PRL to 13,471 ng/ml. Visual field deterioration and increased tumor size (height, 40-43 mm) by computed tomography were documented. A relationship between T injection and exacerbation of the prolactinoma was not recognized until after a second T injection 3 months later. After that therapy, baseline PRL increased from 6,900 to 12,995 ng/ml. The hypothesis that T was aromatized to estradiol, directly stimulating lactotrophs, was supported by an increase in serum estradiol from 24 to 51 pg/ml after the second T injection. Although T treatment is accepted as appropriate therapy for hypogonadism in men with prolactinomas, it may not only interfere with the response of the tumor to BRC therapy, but even stimulate tumor growth and secretion.

Crystal sizes (scanning electron microscopy) and distributions (Coulter Counter) as well as 24-h urinary sodium (Na) and calcium (Ca) excretions (flame atomic absorption) were determined in a group of black South African runners immediately after a marathon and again 3 weeks later. White runners and black and white control subjects were included in the study. Particle volume-size histograms for black controls and black runners were identical. There was no significant difference in the Na excretion of all the groups. However, while urinary Ca excretion was significantly raised in white runners relative to white controls, Ca excretion in black runners was unchanged relative to their controls. It is postulated that the lower rates of urinary Ca excretion may result from lower rates of Ca resorption from bone in response to the cyclical loading of running in black marathon runners. The results of this study suggest that black marathon runners are not prone to the same increased risk of renal stone formation as are white runners.